Free shipping on all orders over $ 500

PF-05231023

Cat. No. M10048
PF-05231023 Structure
Synonym:

PF05231023

Size Price Availability Quantity
10mg USD 210  USD210 In stock
25mg USD 420  USD420 In stock
50mg USD 750  USD750 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM. PF-05231023 suppresses oxidative-stress-induced inflammation in photoreceptors. PF-05231023 decreases the variability of retinal NRF2 levels and displays a trend (non-significant) towards increased NRF2 levels in Akita mice. PF-05231023 (10 mg/kg; i.p.) reduces retinal inflammation in diabetic mice.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 528.55
Formula C26H32N4O8
CAS Number 1037589-69-7
Purity >99%
Solubility DMSO 100 mg/mL
Storage at -20°C
References

[1] Junichiro Sonoda, et al. Horm Mol Biol Clin Investig. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases

[2] Jennifer Q Dong, et al. Br J Clin Pharmacol. Pharmαcοkinetics and phαrmacodynamιcs of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-hυman study

[3] Craig Giragossian, et al. Drυg Metab Dispos. Mechanistic investigation of the preclinιcal pharmαcοkinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate

Related FGFR Products
EOC317

EOC317 (ACTB-1003) is an orally available kinase inhibitor that inhibits FGFR1, VEGFR2, and tie-2 with IC50 values of 6,2, and 4 nM, respectively.

PRN1371

PRN1371 is a highly selective and potent inhibitor of FGFR1-4 and CSF1R against FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R IC50 The values are 0.6, 1.3, 4.1, 19.3, and 8.1 nM, respectively.

Alofanib (RPT835)

Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect with IC50 <10 nM on FGF2-induced phoshphorylation of FRS2a in KATO III cells.

ASP5878

ASP5878 is a novel selective FGFR inhibitor with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3 and 4, respectively.

Futibatinib (TAS-120)

Futibatinib (TAS-120) is an oral bioavailable, highly selective and irreversible FGFR inhibitor with IC50 of 3.9, 1.3, 1.6 and 8.3 nM against the four FGFR 1-4 subtypes, respectively. Futibatinib inhibited mutant and wild-type FGFR2 with IC50 similarity (wild-type FGFR2=0.9 nM; V5651 = 1 to 3 nM; N550H = 3.6 nM. E566G = 2.4 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: PF-05231023, PF05231023 supplier, FGFR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.